|
|
|
ONLINE FEATURES
Book Reviews
BW Video
Columnists
Interactive Gallery
Newsletters
Past Covers
Philanthropy
Podcasts
Special Reports
BLOGS
Auto Beat
Bangalore Tigers
Blogspotting
Brand New Day
Byte of the Apple
Economics Unbound
Eye on Asia
Fine On Media
Green Biz
Hot Property
Investing Insights
Management IQ
NEXT: Innovation
NussbaumOnDesign
Tech Beat
Working Parents
TECHNOLOGY
J.D. Power Ratings
Product Reviews
Tech Stats
Wildstrom: Tech Maven
AUTOS
Home Page
Auto Reviews
Classic Cars
Car Care & Safety
Hybrids
INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip INVESTING Investing: Europe Annual Reports BW 50 S&P Picks & Pans Stock Screeners Free S&P Stock Report SCOREBOARDS Hot Growth 100 Mutual Funds Info Tech 100 S&P 500 B-SCHOOLS Undergrad Programs MBA Blogs MBA Profiles MBA Rankings Who's Hiring Grads |  |
JULY 25, 2005
Is Merck Rallying After That Nasty Tumble?  Although most analysts who track Merck (MRK
) (MRK) remain bearish on the beleaguered drugmaker, some upbeat investors are buying. Merck pulled its Vioxx/ COX-2 Inhibitor for arthritis (11% of sales) off the market in September after studies linked it to increased risk of heart attacks. The stock plunged -- from 45 on Sept. 29 to 26 by Nov. 9 -- but has since crept up to 31.62. Still, it's selling at a "fire-sale price," says Carl Birkenbach of Birkenbach Management, which has bought shares. Despite the "negative aura" surrounding Merck, he sees it beating analysts' reduced 2006 consensus earnings forecast of $2.41 a share; he predicts $2.50. The price, he says, already reflects the lawsuits that face Merck. It does not, however, take account, he adds, of new drugs in the pipeline -- and the likely return of Vioxx. He notes that a panel in Canada recently recommended allowing Vioxx back into the market. In February a U.S. group called for similar action. Michael Krensavage of Raymond James & Associates, a rare bull, tags Merck a "strong buy" because its 4.8% dividend provides an "attractive return." Its new drugs include a series of vaccines, such as Gardasil, for cervical cancer. His price target is 42.
Note: Unless otherwise noted, neither the sources cited in Inside Wall Street nor their firms hold positions in the stocks under discussion. Similarly, they have no investment banking or other financial relationships with them.  By Gene G. Marcial
BW MALL
SPONSORED LINKS
Get BusinessWeek directly on your desktop with our RSS feeds.
Buy a link now! Add BusinessWeek news to your Web site with our headline feed. Click to buy an e-print or reprint of a BusinessWeek or BusinessWeek Online story or video. To subscribe online to BusinessWeek magazine, please click here. Learn more, go to the BusinessWeekOnline home page  | | |
 Copyright 2005, by The McGraw-Hill Companies Inc. All rights reserved.Terms of Use | Privacy Notice |
Printer-Friendly Version